Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kidney treatments developer NephroGenex has signed two licensing agreements, providing it with a kidney-specific molecular profiling technology and inhibitors of a novel kinase target for renal disease.
Subscribe to our email newsletter
NephroGenex has acquired exclusive commercial rights to the glomerular transcriptome profiling technology developed by doctors at the world-renowned Karolinska Institute in Stockholm, Sweden. This technology utilizes GlomChip, a DNA chip developed to measure expressed genes in the kidney’s filtration unit, the glomerulus. This molecular profiling technology is being used to identify key renal-specific pathogenic pathways that emerge in the leading kidney diseases.
Current treatments for the leading renal diseases target causative systemic pathologies, such as blood pressure and immunological response. These treatments are at best marginally effective, and do not appreciably delay the progression to end stage renal disease (ESRD).
Targeting renal-specific pathology has shown promise in preclinical studies. However, the diversity of disease processes that are activated in the kidney due to diabetes, hypertension, circulating IgA and lupus, have hampered drug development efforts.
NephroGenex has also acquired exclusive commercial rights to a proprietary GPBP kinase technology and inhibitors being developed at the Fundacion Valenciana de Investigaciones Biomedicas in Valencia, Spain.